Propranol40 mg

Propranol 40 mg is a non-selective beta-adrenergic blocking agent used for a range of cardiovascular and other conditions. Its evidence-based uses include:

Established / FDA-approved uses

• Hypertension (alone or with other antihypertensive agents)
• Angina pectoris due to coronary atherosclerosis
• Cardiac arrhythmias, including certain supraventricular tachyarrhythmias and adjunctive rate control in atrial fibrillation
• Reducing cardiovascular mortality after myocardial infarction
• Migraine prophylaxis (prevention, not treatment of an acute attack)
• Hypertrophic subaortic stenosis, to reduce outflow obstruction symptoms
• Pheochromocytoma, as an adjunct to alpha-adrenergic blockade (never used alone)

Guideline-supported / commonly used off-label

• Essential tremor, to reduce tremor amplitude
• Situational (performance) anxiety, to reduce physical symptoms such as tremor and palpitations

The specific indication and dose must be individualized by a physician; Propranol 40 mg is not indicated for hypertensive emergencies.

Each tablet/capsule contains Propranol 40 mg as the active pharmaceutical ingredient, available in various strengths (e.g., 10 mg, 20 mg, 40 mg, 80 mg) as immediate-release tablets, extended-release capsules, and oral solution, along with standard pharmaceutical excipients.

Propranol 40 mg is a non-cardioselective beta-adrenergic receptor blocking agent that has been used for decades in the management of hypertension, angina, arrhythmias, and several non-cardiac conditions such as migraine prevention and essential tremor. It blocks both beta-1 and beta-2 adrenergic receptors, distinguishing it from cardioselective beta-blockers.

Propranol 40 mg is available in immediate-release and extended-release oral formulations, allowing flexible dosing depending on the indication being treated.

Propranol 40 mg belongs to the therapeutic class of non-selective beta-adrenergic receptor blocking agents (beta-blockers).

Propranol 40 mg competitively blocks beta-1 and beta-2 adrenergic receptors, without significant intrinsic sympathomimetic activity. Blockade of beta-1 receptors in the heart decreases heart rate, myocardial contractility, and cardiac output, and reduces reflex orthostatic tachycardia. Blockade of beta-2 receptors in bronchial and vascular smooth muscle can produce bronchoconstriction and peripheral vasoconstriction, which explains its caution in reactive airway disease.

The antihypertensive mechanism of Propranol 40 mg is not fully established but is thought to involve decreased cardiac output, inhibition of renin release from the kidney, and reduction of central sympathetic outflow. In angina, it reduces myocardial oxygen demand by lowering heart rate, contractility, and blood pressure. In migraine prophylaxis and tremor, the exact mechanism is unclear but may relate to central beta-adrenergic blockade.

Propranol 40 mg immediate-release tablets/solution are usually taken before meals and at bedtime as directed; extended-release capsules are taken once daily, generally in the morning, and should be swallowed whole without crushing or chewing. Take at the same time(s) each day and do not stop taking Propranol 40 mg suddenly without consulting a physician.

Propranol 40 mg has several clinically significant drug interactions:

• Other beta-blockers: additive bradycardia and hypotension; concurrent use generally avoided.
• Calcium channel blockers (verapamil, diltiazem): additive negative effects on heart rate, AV conduction, and cardiac contractility; risk of severe bradycardia, AV block, or heart failure.
• Clonidine: if both are being discontinued, propranolol should be withdrawn several days before clonidine to reduce the risk of rebound hypertension.
• Insulin and oral hypoglycemic agents: Propranol 40 mg can mask the tachycardia and tremor of hypoglycemia, delaying recognition in diabetic patients.
• NSAIDs: may reduce the antihypertensive effect of Propranol 40 mg through sodium/fluid retention and prostaglandin inhibition.
• Rizatriptan: Propranol 40 mg increases rizatriptan plasma levels; a lower rizatriptan dose is recommended when used together.
• CYP2D6/CYP1A2 inhibitors (e.g., fluoxetine, quinidine, cimetidine): may increase propranolol blood levels and effect.

Common and important adverse effects of Propranol 40 mg include:

• Fatigue, lethargy, dizziness
• Bradycardia and hypotension
• Cold extremities, Raynaud's-type peripheral vasoconstriction
• Bronchospasm, particularly in patients with reactive airway disease (see Contraindications)
• Vivid dreams, sleep disturbances, and rarely depression
• Gastrointestinal upset: nausea, vomiting, diarrhea, constipation
• Masking of hypoglycemia symptoms in diabetic patients
• Rare: bronchospasm-related emergencies, heart failure exacerbation, and (very rarely) severe skin reactions

Propranol 40 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, under close physician supervision. Use near delivery has been associated with neonatal bradycardia, hypoglycemia, and respiratory depression, so newborns should be monitored if exposure occurred close to term. Propranol 40 mg is excreted in breast milk; a physician should be consulted to weigh the benefits of breastfeeding against potential infant exposure, and the infant should be observed for signs of beta-blockade if breastfeeding is continued.

Propranol 40 mg should not be discontinued abruptly, as sudden withdrawal can precipitate rebound angina, myocardial infarction, or severe hypertension in susceptible patients; discontinuation should always be gradual and physician-supervised.

• Use with caution in patients with diabetes mellitus, as it can mask signs of hypoglycemia (see Interactions).
• Use with caution in patients with a history of reactive airway disease even without a formal asthma diagnosis, due to risk of bronchospasm.
• Use with caution in patients with peripheral vascular disease, as symptoms may worsen.
• Use with caution in hepatic impairment, since propranolol is extensively metabolized by the liver.
• May mask signs of developing thyrotoxicosis; abrupt withdrawal in thyrotoxic patients may precipitate thyroid storm.

Overdose of Propranol 40 mg can cause severe bradycardia, hypotension, bronchospasm, heart failure, seizures, and loss of consciousness, and can be life-threatening. If overdose is suspected, seek immediate emergency medical attention or contact a poison control center right away; do not attempt to manage an overdose at home. Treatment is supportive and must be provided in a hospital setting under medical supervision.

Store Propranol 40 mg at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Elderly: Dose selection should start at the lower end of the dosing range due to reduced clearance of Propranol 40 mg in older adults; monitor closely for bradycardia and hypotension.

Renal impairment: No specific dose adjustment is generally required, but caution and monitoring are advised.

Hepatic impairment: Since Propranol 40 mg undergoes extensive hepatic metabolism, dose reduction and careful monitoring are recommended in patients with significant liver disease.

Pediatric patients: See Pediatric Uses.

Duration of treatment with Propranol 40 mg depends on the indication; chronic conditions such as hypertension, angina, and tremor typically require long-term, ongoing therapy as directed by a physician, with periodic reassessment. Treatment should never be stopped abruptly (see Precautions and Warnings).

Propranol 40 mg belongs to the non-selective beta-adrenergic receptor blocking agent (beta-blocker) drug class.

Propranol 40 mg works by competitively blocking beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, cardiac output, and renin release, thereby lowering blood pressure and myocardial oxygen demand.

Category C

Safety and effectiveness of Propranol 40 mg for general cardiovascular indications in pediatric patients have not been fully established for all age groups, and use should be under specialist supervision. A specific oral solution formulation of Propranol 40 mg is approved for treatment of proliferating infantile hemangioma requiring systemic therapy, with weight-based dosing initiated and monitored by a physician experienced in this use. Bronchospasm, hypoglycemia, and bradycardia have been reported in pediatric use, requiring close monitoring.